Gavin Giovannoni

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint [PANDAS: overview of the hypothesis]
    Gavin Giovannoni
    Rev Bras Psiquiatr 26:222-3. 2004
  2. ncbi request reprint Gluten Ataxia and Post-Streptococcal Central Nervous System Syndromes: Emerging Immune-mediated Disorders of the Central Nervous System?
    Adrian Wills
    Institute of Neurology, Queen Square, London WC1 3BG, United Kingdom
    Curr Treat Options Neurol 7:183-189. 2005
  3. ncbi request reprint Optimising MS disease-modifying therapies: antibodies in perspective
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    J Neurol 251:v30-v35. 2004
  4. ncbi request reprint Infectious causes of multiple sclerosis
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Lancet Neurol 5:887-94. 2006
  5. ncbi request reprint Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK
    Neurology 61:S13-7. 2003
  6. pmc Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
    G Giovannoni
    Institute of Neurology, Queen Square, London WC1N 3BG, UK
    J Neurol Neurosurg Psychiatry 68:423-8. 2000
  7. ncbi request reprint Management of secondary-progressive multiple sclerosis
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    CNS Drugs 18:653-69. 2004
  8. ncbi request reprint Fatigue is not associated with raised inflammatory markers in multiple sclerosis
    G Giovannoni
    Department of Neurochemistry, Institute of Neurology, London, United Kingdom
    Neurology 57:676-81. 2001
  9. ncbi request reprint Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis
    G Giovannoni
    Department of Neurochemistry, University of London, UK
    J Neurol 248:487-95. 2001
  10. ncbi request reprint Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis
    G Giovannoni
    National Hospital for Neurology and Neurosurgery and Institute of Neurology, London, UK
    Eur Neurol 44:222-8. 2000

Detail Information

Publications110 found, 100 shown here

  1. ncbi request reprint [PANDAS: overview of the hypothesis]
    Gavin Giovannoni
    Rev Bras Psiquiatr 26:222-3. 2004
  2. ncbi request reprint Gluten Ataxia and Post-Streptococcal Central Nervous System Syndromes: Emerging Immune-mediated Disorders of the Central Nervous System?
    Adrian Wills
    Institute of Neurology, Queen Square, London WC1 3BG, United Kingdom
    Curr Treat Options Neurol 7:183-189. 2005
    ..Apart from the diagnosis and management of SC, no consensus exists regarding the diagnosis and management of the other clinical entities within this group of disorders...
  3. ncbi request reprint Optimising MS disease-modifying therapies: antibodies in perspective
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    J Neurol 251:v30-v35. 2004
    ....
  4. ncbi request reprint Infectious causes of multiple sclerosis
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Lancet Neurol 5:887-94. 2006
  5. ncbi request reprint Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK
    Neurology 61:S13-7. 2003
    ..Strategies used to prevent or reverse the development of NAbs with other biologic compounds, including improvements in the manufacturing process, immunosuppression, induction of tolerance, and deimmunization, will be reviewed...
  6. pmc Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
    G Giovannoni
    Institute of Neurology, Queen Square, London WC1N 3BG, UK
    J Neurol Neurosurg Psychiatry 68:423-8. 2000
    ..The clinical features and guidelines for managing this syndrome are discussed. A set of diagnostic criteria for further investigating this condition is proposed...
  7. ncbi request reprint Management of secondary-progressive multiple sclerosis
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    CNS Drugs 18:653-69. 2004
    ..The aim of symptomatic therapies should not only be to reduce neurological impairments but also to decrease disability and handicap and to improve the emotional well-being and health-related quality of life of patients with SPMS...
  8. ncbi request reprint Fatigue is not associated with raised inflammatory markers in multiple sclerosis
    G Giovannoni
    Department of Neurochemistry, Institute of Neurology, London, United Kingdom
    Neurology 57:676-81. 2001
    ..The pathogenesis of fatigue in patients with MS is poorly understood...
  9. ncbi request reprint Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis
    G Giovannoni
    Department of Neurochemistry, University of London, UK
    J Neurol 248:487-95. 2001
    ..These findings, although preliminary, pose interesting questions on the role of nitric oxide in the pathogenesis of MS. Inducible NO production in the early stages of the disease may be beneficial...
  10. ncbi request reprint Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis
    G Giovannoni
    National Hospital for Neurology and Neurosurgery and Institute of Neurology, London, UK
    Eur Neurol 44:222-8. 2000
    ..Failure to do this may explain the poor and unpredictable correlations between immunological markers and Gd-enhanced MRI activity, which cannot be accurately aged in cross-sectional and serial monthly MRI studies...
  11. pmc Multiple sclerosis cerebrospinal fluid biomarkers
    Gavin Giovannoni
    Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK
    Dis Markers 22:187-96. 2006
    ..Bulk biomarkers of the neurodegenerative process such as glial fibrillary acidic protein (GFAP) and neurofilaments (NF) have advantages over intermittent inflammatory markers...
  12. ncbi request reprint Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis
    J Ludovic Croxford
    Department of Neuroinflammation, Institute of Neurology, University College London, London WC1N 1PJ, United Kingdom
    J Neuroimmunol 193:120-9. 2008
    ..This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS...
  13. doi request reprint Antineuronal antibodies in Parkinson's disease
    Bart P C van de Warrenburg
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, United Kingdom
    Mov Disord 23:958-63. 2008
    ..We conclude that ANAs do not play a role in the majority of patients with IPD, but might be relevant in the pathogenesis of IPD with atypical features...
  14. doi request reprint Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis
    Fabiola Puentes
    Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    J Neurol Neurosurg Psychiatry 85:274-8. 2014
    ....
  15. pmc PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results
    Alastair J Noyce
    Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK
    J Neurol Neurosurg Psychiatry 85:31-7. 2014
    ..To present methods and baseline results for an online screening tool to identify increased risk for Parkinson's disease (PD) in the UK population...
  16. doi request reprint Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis
    Sharmilee Gnanapavan
    Department of Neuroimmunology, Institute of Neurology, London, UK
    Autoimmunity 45:298-303. 2012
    ..These data further support neurofilament levels as a good surrogate measure of neurodegeneration and their potential use as a surrogate endpoint in neuroprotective studies...
  17. ncbi request reprint Post-streptococcal autoimmune neuropsychiatric disease presenting as paroxysmal dystonic choreoathetosis
    Russell C Dale
    Department of Neurology, Great Ormond Street Hospital NHS Trust and Institute of Child Health, London, United Kingdom
    Mov Disord 17:817-20. 2002
    ..We propose that autoantibodies produced in post-streptococcal neuropsychiatric disease cause alteration in neurotransmission, possibly secondary to ion channel binding...
  18. ncbi request reprint Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis
    Gareth Pryce
    Department of Neuroinflammation, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ, UK
    J Neuroimmunol 165:41-52. 2005
    ....
  19. pmc Fingolimod modulates microglial activation to augment markers of remyelination
    Samuel J Jackson
    Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
    J Neuroinflammation 8:76. 2011
    ..In addition, it is brain penetrant and has been shown to exert multiple effects on nervous system cells...
  20. pmc Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
    Ee Tuan Lim
    Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK
    J Negat Results Biomed 3:4. 2004
    ..Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures...
  21. doi request reprint Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
    Gavin Giovannoni
    Queen Mary University London, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
    Lancet Neurol 10:329-37. 2011
    ....
  22. pmc Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
    Ching Hua Lu
    From the Centre for Neuroscience and Trauma C H L, G G, J K, A M, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London Sobell Department of Motor Neuroscience and Movement Disorders C H L, L G, Departments of Neuroinflammation A P, Neurodegenerative Disease P F, Molecular Neuroscience K S, and Clinical Neuroscience R O, and MRC Centre for Neuromuscular Diseases R O, L G, UCL Institute of Neurology, London MRC Integrative Epidemiology Unit C M W, University of Bristol Nuffield Department of Clinical Neurosciences E G, K T, M R T, University of Oxford Department of Medical Statistics N P, London School of Hygiene and Tropical Medicine, London, UK UmanDiagnostics N N, Umea, Sweden Medicine Clinical Trial Unit M F, Musgrove Park Hospital, Taunton, UK National Hospital for Neurology and Neurosurgery R O, R H, A M, London, UK Neurology J K, University Hospital Basel, Switzerland North East London and Essex MND Care and Research Centre A M, China CDC
    Neurology 84:2247-57. 2015
    ..To test blood and CSF neurofilament light chain (NfL) levels in relation to disease progression and survival in amyotrophic lateral sclerosis (ALS)...
  23. pmc Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression
    Sharmilee Gnanapavan
    Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom
    PLoS ONE 8:e70019. 2013
    ..The current study was an additional study to investigate the value of neurofilament (NfH) and other biomarkers in predicting prognosis and/or response to treatment...
  24. doi request reprint Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis
    Sarah Al-Izki
    1 Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Brain 137:92-108. 2014
    ..This class of agents inhibit microglial activity and neural sodium loading, which are both thought to contribute to progressive neurodegeneration in multiple sclerosis and possibly other neurodegenerative diseases. ..
  25. doi request reprint The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis
    Eleanor James
    Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
    Mult Scler 19:1571-9. 2013
    ..Further larger, more prolonged studies are merited. ..
  26. pmc Progression in multiple sclerosis is associated with low endogenous NCAM
    Sharmilee Gnanapavan
    Department of Neuroimmunology, Institute of Neurology, London, UK
    J Neurochem 125:766-73. 2013
    ..Our findings suggest that depletion of NCAM is one of the factors associated with or possibly responsible for disease progression in MS...
  27. ncbi request reprint The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders
    Gavin Giovannoni
    Department of Neuroimmunology, Institute of Neurology, Queen Square, London WC1N 3BG, UK
    J Neuroimmunol 180:29-32. 2006
    ..We have extended this technique to individual clones and followed the maturation of clones during the course of herpes encephalitis. This has important implications for our understanding of the pathogenesis of multiple sclerosis...
  28. ncbi request reprint Quantitative demonstration of intrathecal synthesis of high affinity immunoglobulin G in herpes simplex encephalitis using affinity-mediated immunoblotting
    Miles D Chapman
    Department of Neuroimmunology, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    J Neuroimmunol 185:130-5. 2007
    ..Digitisation of the blots enabled further analysis. We showed that the clones of antigen-specific IgG, which were produced intrathecally, were of higher relative affinity than polyclonal antigen-specific IgG...
  29. ncbi request reprint Antineuronal antibody status and phenotype analysis in Tourette's syndrome
    Davide Martino
    Department of Neuroinflammation, Institute of Neurology, University College London, London, United Kingdom
    Mov Disord 22:1424-9. 2007
    ..14; P = 0.002; 95% confidence interval 0.04-0.49). ANeA status does not differentiate a specific phenotype of GTS...
  30. pmc Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis
    Sofia Sisay
    Neuroimmunology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
    PLoS ONE 8:e76907. 2013
    ..Importantly, it adds a note of caution for the translational value of some transgenic/gene knockout and other studies on low-EAE susceptibility backgrounds with inconsistent disease course and susceptibility. ..
  31. doi request reprint The effect of gender in clinically isolated syndrome (CIS): a meta-analysis
    Ruth Dobson
    Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
    Mult Scler 18:600-4. 2012
    ..There has previously been little work examining the effect of gender on the development and progression of CIS...
  32. ncbi request reprint Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease
    Russell C Dale
    Department of Neuroinflammmation, Institute of Neurology, University College London, and Neurosciences Unit, Great Ormond Street Hospital and Institute of Child Health, London WC1N 3JJ, UK
    J Neuroimmunol 172:187-97. 2006
    ..GAS also expresses glycolytic enzymes on cell surfaces that have 0-49% identity with human NGE, suggesting molecular mimicry and autoimmune cross-reactivity may be the pathogenic mechanism in post-streptococcal CNS disease...
  33. ncbi request reprint Antibasal ganglia antibodies and their relevance to movement disorders
    Davide Martino
    Institute of Neurology, University College London, UK
    Curr Opin Neurol 17:425-32. 2004
    ..This review summarizes the most recent studies concerning antibasal ganglia antibodies, focusing on the associated phenotypes and the hypotheses concerning their pathogenicity...
  34. doi request reprint Subtle motor disturbances in PREDICT-PD participants
    Alastair J Noyce
    Department of Molecular Neuroscience, Reta Lila Weston Institute, UCL Institute of Neurology, London, UK
    J Neurol Neurosurg Psychiatry . 2016
    ..We sought to determine whether higher risk participants (defined as those above the 15th centile of risk estimates) were more likely to have mild parkinsonian signs compared with lower risk participants...
  35. doi request reprint Growth associated protein (GAP-43): cloning and the development of a sensitive ELISA for neurological disorders
    Sharmilee Gnanapavan
    Department of Neuroimmunology, Institute of Neurology, Queen Square, London, UK Electronic address
    J Neuroimmunol 276:18-23. 2014
    ..001, and movement disorders and multiple sclerosis; p<0.0001) compared to controls, aside from CNS infections. GAP-43 is preferentially reduced in the CSF of neurological disorders associated with neurodegeneration. ..
  36. doi request reprint Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis
    Sara Leddy
    Barts and the London School of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, 4 Newark Street, London, E1 2AT, UK
    J Neurol 260:2505-10. 2013
    ..Agreement was better in patients with higher scores. Overall patient satisfaction with the web-based assessment was high. An internet-based assessment tool is likely to prove an invaluable tool in the long-term monitoring in MS...
  37. pmc Increased neurofilament light chain blood levels in neurodegenerative neurological diseases
    Johanna Gaiottino
    Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom Bone and Joint Research Unit, John Vane Science Centre, Queen Mary University of London, London, United Kingdom
    PLoS ONE 8:e75091. 2013
    ..This study aimed to validate the quantification of the Nf light chain (NfL) in blood samples, as a biofluid source easily accessible for longitudinal studies...
  38. doi request reprint Development of resistance to biologic therapies with reference to IFN-β
    Rachel A Farrell
    Department of Neuroinflammation, UCL Institute of Neurology, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London E1 2AT, UK
    Rheumatology (Oxford) 51:590-9. 2012
    ....
  39. ncbi request reprint Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage
    Konrad Rejdak
    Department Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK
    J Neurol Sci 219:71-6. 2004
    ....
  40. ncbi request reprint Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis
    Rachel A Farrell
    Department of Neuroimmunology, Institute of Neurology, London, UK
    Mult Scler 13:567-77. 2007
    ....
  41. pmc A Risk Score for Predicting Multiple Sclerosis
    Ruth Dobson
    Queen Mary University London Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    PLoS ONE 11:e0164992. 2016
    ..We set out to develop an MS risk score integrating both genetic and environmental risk factors. We used this score to identify siblings at extremes of MS risk and attempted to validate the score using brain MRI...
  42. doi request reprint PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease
    Alastair J Noyce
    University College London Institute of Neurology, University College London, London, UK
    Mov Disord . 2017
    ..A number of early features can precede the diagnosis of Parkinson's disease (PD)...
  43. pmc Bradykinesia-akinesia incoordination test: validating an online keyboard test of upper limb function
    Alastair J Noyce
    Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
    PLoS ONE 9:e96260. 2014
    ..An online version has now been designed for use in a wider clinical context and the research setting...
  44. doi request reprint Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers
    Ruth Dobson
    Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London, UK
    J Med Virol 85:128-31. 2013
    ..23. Although sensitivity and specificity appear adequate, the poor negative predictive value and kappa coefficient are of major concern. Care must be taken when selecting assays for experimental use...
  45. pmc Meta-analysis of early nonmotor features and risk factors for Parkinson disease
    Alastair J Noyce
    Institute of Neurology, University College London, London, United Kingdom
    Ann Neurol 72:893-901. 2012
    ..To evaluate the association between diagnosis of Parkinson disease (PD) and risk factors or early symptoms amenable to population-based screening...
  46. doi request reprint Neurofilament ELISA validation
    Axel Petzold
    Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
    J Immunol Methods 352:23-31. 2010
    ..As these markers become more widely used, an inter-laboratory validation study is required to identify assay criteria for high quality performance...
  47. ncbi request reprint Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis
    Gavin Giovannoni
    Neuroimmunology Unit, Institute of Cell and Molecular Science, Queen Mary University London, London, United Kingdom
    Clin Ther 29:1128-45. 2007
    ..It was developed with the aim of maximizing the treatment benefit for patients with multiple sclerosis (MS) by improving injection tolerability and reducing the development of neutralizing antibodies (NAbs)...
  48. doi request reprint A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
    Gavin Giovannoni
    Queen Mary University London, the Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    N Engl J Med 362:416-26. 2010
    ..Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis...
  49. ncbi request reprint No evidence for production of intrathecal immunoglobulin G against Acinetobacter or Pseudomonas in multiple sclerosis
    Miles D Chapman
    Department of Neuroimmunology, Institute of Neurology, Queen Square, London, UK
    Eur Neurol 53:27-31. 2005
    ..other neurological diseases, and so conclude that A. calcoaceticus and P. aeruginosa are unlikely to be implicated in the pathogenesis of MS...
  50. ncbi request reprint Autoaggressive immune-mediated movement disorders
    Davide Martino
    Institute of Neurology, Department of Neuroimmunology, University College London, London, United Kingdom
    Adv Neurol 96:320-35. 2005
    ....
  51. ncbi request reprint Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity
    Russell C Dale
    Neurosciences Unit, Great Ormond Street Hospital and Institute of Child Health, and Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Brain 127:21-33. 2004
    ..We believe an EL-like syndrome is still prevalent, and propose that this syndrome may be secondary to autoimmunity against deep grey matter neurons...
  52. ncbi request reprint CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome?
    Andrew J Church
    Neuroimmunology Unit, Neuroinflammation Department, Institute of Neurology, Room 917, Queen Square, London WC1N 3BG, UK
    J Neuroimmunol 136:149-53. 2003
    ..OCB were found in 46% of acute SC, ABGA were in 93% of acute SC and 50% of persistent SC was of IgG(1) and IgG(3) subclass. These findings support an autoantibody pathogenesis...
  53. doi request reprint Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies
    Connie Luk
    Reta Lila Weston Institute of Neurological Studies and Department of Molecular Neuroscience, UCL Institute of Neurology, 1 Wakefield Street, London WC1N1PJ, UK
    J Neurosci Methods 180:34-42. 2009
    ..With this, we have for the first time developed ELISAs for quantification of 3R- and 4R-tau isoforms in pathological samples. These could prove useful in the pathological investigation and differential diagnosis of tauopathies...
  54. ncbi request reprint Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis
    Russell C Dale
    Neurosciences Unit, Institute of Child Health, London, UK
    Dev Med Child Neurol 44:485-9. 2002
    ..Acute IBSN is part of the poststreptococcal autoimmune neuropsychiatric spectrum. An autoimmune aetiology should be considered in this phenotype, as immunomodulatory therapies may reduce morbidity and mortality...
  55. doi request reprint Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids
    Gareth Pryce
    Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London, E1 2AT, UK
    J Neuroimmune Pharmacol 10:281-92. 2015
    ....
  56. pmc A service development study of the assessment and management of fracture risk in Parkinson's disease
    Samuel Shribman
    Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University London, 4 Newark Street, London, E1 2AT, UK
    J Neurol 261:1153-9. 2014
    ....
  57. pmc Neuroprotection in a novel mouse model of multiple sclerosis
    Katie Lidster
    Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
    PLoS ONE 8:e79188. 2013
    ..These novel approaches have relevance to the future treatment of neurodegeneration of MS, which has so far evaded treatment. ..
  58. doi request reprint Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes
    Ruth Dobson
    Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London, UK
    Pract Neurol 13:70-9. 2013
    ..Here, we discuss the literature on bone health, falls and fractures in MS and akinetic-rigid syndromes, and suggest strategies to investigate and manage bone health in the neurology clinic...
  59. doi request reprint Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis
    Ruth Dobson
    Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London, E1 2AT, UK
    J Neurol 260:1272-85. 2013
    ..However, this does not extend to all conditions studied. Given the nonspecific clinical presentation of thyroid disease, it should be considered in all people with MS presenting with nonspecific symptoms...
  60. ncbi request reprint Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon
    Monica Marta
    Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK
    CNS Neurol Disord Drug Targets 11:610-23. 2012
    ..The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing...
  61. doi request reprint Neural cell adhesion molecule--description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders
    Sharmilee Gnanapavan
    Department of Neuroimmunology, Institute of Neurology, London, UK
    J Neuroimmunol 225:118-22. 2010
    ..Significant reductions were found between controls and multiple sclerosis, Alzheimer's disease and meningitis...
  62. ncbi request reprint Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis
    Ee Tuan Lim
    University College London, Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    Expert Rev Neurother 5:379-90. 2005
    ..A number of new approaches likely to manipulate the immunopathogenesis of multiple sclerosis and which may ultimately allow for the development of more effective immunotherapy are also highlighted...
  63. ncbi request reprint Soluble adhesion molecules in acute disseminated encephalomyelitis
    Davide Martino
    Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Pediatr Neurol 33:255-8. 2005
    ..Further larger studies are required including serial measurements and cerebrospinal fluid analysis...
  64. ncbi request reprint Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a
    Benedicte Dubois
    Institute of Neurology, London, UK
    J Neurol 250:1037-43. 2003
    ..One of these is a cellular down-regulation of gelatinase B or matrix metalloproteinase-9 (MMP-9), which is known from biochemical, biological and immunohistochemical evidences to play a disease-promoting role in MS...
  65. doi request reprint Evidence for acute neurotoxicity after chemotherapy
    Axel Petzold
    Department of Neuroimmunology, UCL Institute of Neurology, Queen Square, London, United Kingdom
    Ann Neurol 68:806-15. 2010
    ..Neurotoxicity adversely affects patients' quality of life. The objective of this study is to examine whether there is evidence of acute neurotoxicity...
  66. ncbi request reprint Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies
    Mark J Edwards
    Sobell Department of Movement Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London, United Kingdom
    Mov Disord 19:1190-6. 2004
    ..We suggest that there might be a causal relationship between ABGA and the clinical syndrome in these cases and that ABGA should be considered as a possible etiology for adult-onset tics...
  67. doi request reprint Depletion of CD52 positive cells inhibits the development of CNS autoimmune disease, but deletes an immune-tolerance promoting CD8 T cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
    Stephanie von Kutzleben
    Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, United Kingdom
    Immunology . 2016
    ..This article is protected by copyright. All rights reserved...
  68. doi request reprint Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
    Gavin Giovannoni
    Department of Neurosciences, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK
    Pract Neurol 16:389-93. 2016
    ..We also discuss the caveats and subtleties associated with sequencing DMTs in MS and the complex decision making involved. ..
  69. pmc Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
    Ching Hua Lu
    Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, UK
    J Neurol Neurosurg Psychiatry 86:565-73. 2015
    ..To investigate the role of longitudinal plasma neurofilament heavy chain protein (NfH) levels as an indicator of clinical progression and survival in amyotrophic lateral sclerosis (ALS)...
  70. pmc The refinement of genetic predictors of multiple sclerosis
    Giulio Disanto
    Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    PLoS ONE 9:e96578. 2014
    ..This is still unlikely to be clinically useful but a more complete understanding of the complexity underlying MS aetiology and the inclusion of environmental risk factors will aid future attempts of disease prediction...
  71. doi request reprint Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE)
    Christopher Bolton
    Neuroimmunology Unit, Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London, E12 AT, UK
    Inflamm Res 62:659-67. 2013
    ....
  72. doi request reprint Current and future role of interferon beta in the therapy of multiple sclerosis
    Rachel A Farrell
    Institute of Neurology, University College London, London, United Kingdom
    J Interferon Cytokine Res 30:715-26. 2010
    ..We also review the efficacy of each drug, use of combination therapy strategies, and the potential role of the interferon beta preparations in the future...
  73. doi request reprint Multiple sclerosis: risk factors, prodromes, and potential causal pathways
    Sreeram V Ramagopalan
    Blizard Institute of Cell and Molecular Science, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
    Lancet Neurol 9:727-39. 2010
    ....
  74. ncbi request reprint Multiple sclerosis: the environment and causation
    Gavin Giovannoni
    Institute of Cell and Molecular Science, Queen Mary University London, London, UK
    Curr Opin Neurol 20:261-8. 2007
    ..We review current thinking on the aetiology of multiple sclerosis, how genetic susceptibility interacts with environmental risk factors at the population level, multiple sclerosis-associated risk factors and contemporary causation theory...
  75. ncbi request reprint Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
    Gareth Pryce
    Department of Neuroinflammation, Institute of Neurology, University College London, London, UK
    Brain 126:2191-202. 2003
    ..Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases...
  76. pmc Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
    Gavin Giovannoni
    Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK
    J Neurol 261:316-23. 2014
    ..0574; less active RRMS 46 % reduction, p = 0.0383; interaction p = 0.22) vs. placebo. DAC HYP efficacy was similar across the spectrum of MS disease activity as assessed prior to treatment initiation. ..
  77. pmc Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept
    Inês Brás Marques
    Queen Mary University London, Blizard Institute, 4 Newark Street, London, E1 1AT, UK
    BMC Neurol 14:237. 2014
    ..Several disorders may present with mononeuritis multiplex and the etiological diagnosis can be challenging...
  78. doi request reprint Individualizing treatment goals and interventions for people with MS
    Gavin Giovannoni
    Centre for Neuroscience and Trauma, Barts and the London School of Medicine and Dentistry, London, UK
    Curr Opin Neurol 25:S20-7. 2012
    ..These issues have increased in importance with the availability of new disease-modifying therapies and will continue to do so as more novel treatments are approved...
  79. ncbi request reprint Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis
    Selina Davies
    Department of Infectious Diseases and Transplantation Biology Group, MRC Clinical Sciences Center, Imperial College, Hammersmith Hospital, London, UK
    J Neuropathol Exp Neurol 64:371-7. 2005
    ..This may argue against a simple causal role of epitope spread in driving progression, as has been suggested in experimental allergic encephalomyelitis...
  80. ncbi request reprint Emerging therapies in multiple sclerosis
    Rachel Farrell
    Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    Expert Opin Emerg Drugs 10:797-816. 2005
    ..Many of the treatments discussed in this review are still at early stages of development, but provide exciting potential treatment options; others have proved disappointing in larger extended-phase studies...
  81. ncbi request reprint PANDAS: overview of the hypothesis
    Gavin Giovannoni
    Department of Neuroinflammnation, Institute of Neurology, University College London, London, United Kingdom
    Adv Neurol 99:159-65. 2006
  82. doi request reprint The McDonald Criteria for Multiple Sclerosis: time for clarification
    Christopher H Hawkes
    Queen Mary University of London, Neuroscience and Trauma Centre, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
    Mult Scler 16:566-75. 2010
    ..There was uncertainty about how many multiple sclerosis categories were permitted and whether the terms 'possible' and 'probable' were allowable. Further clarification might allow the criteria to be applied more consistently...
  83. ncbi request reprint Surviving stiff-person syndrome: a case report
    Sharmilee Gnanapavan
    Department of Neuroimmunology, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    J Neurol 258:1898-900. 2011
    ..Here we describe the 15 year long management of a subject with SPS who has had a favourable outcome...
  84. ncbi request reprint The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study
    Gerard Davies
    Department of Neuroinflammation, Institute of Neurology, University College London
    Neurology 60:1163-6. 2003
    ..At present, it is not known whether a single band will convert to an oligoclonal response with time...
  85. ncbi request reprint Choreic syndrome and coeliac disease: a hitherto unrecognised association
    Anthony C Pereira
    Sobell Dept of Motor Neuroscience and Movement Disorders, Institute of Neurology, United Kingdom
    Mov Disord 19:478-82. 2004
    ..Unexpectedly, most of these patients showed a notable improvement in their motor symptoms after the introduction of a gluten-free diet...
  86. ncbi request reprint The therapeutic potential of cannabis
    David Baker
    Institute of Neurology, University College London, Queen Square, WC1N 3BG, London, UK
    Lancet Neurol 2:291-8. 2003
    ..Even if the results of these studies are not as positive as many expect them to be, that we are only just beginning to appreciate the huge therapeutic potential of this family of compounds is clear...
  87. ncbi request reprint Antibasal ganglia antibodies and PANDAS
    Davide Martino
    Mov Disord 20:116-7. 2005
  88. ncbi request reprint Neutralising antibodies against interferon beta in multiple sclerosis
    Gavin Giovannoni
    Lancet 363:166-7; author reply 168-9. 2004
  89. ncbi request reprint Patients with clinically isolated syndromes suggestive of MS: does MRI allow earlier diagnosis?
    Gavin Giovannoni
    Neurology 60:6-7. 2003
  90. ncbi request reprint Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b
    Gavin Giovannoni
    Neurology 61:1025; author reply 1025. 2003
  91. ncbi request reprint Obsessive-compulsive disorder and catatonia can be caused by antibasal ganglia antibodies
    Tim Nicholson
    Cogn Behav Neurol 20:260. 2007
  92. ncbi request reprint Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
    Rachel Farrell
    J Int Med Res 36:204-8; author reply 208-10. 2008
  93. ncbi request reprint CSF analysis in suspected MS: do bands aid?
    Rogier Q Hintzen
    Neurology 70:1059-60. 2008
  94. ncbi request reprint Are antibasal ganglia antibodies important, and clinically useful?
    Davide Martino
    Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
    Pract Neurol 7:32-41. 2007
  95. ncbi request reprint Incidence of anti-brain antibodies in children with obsessive-compulsive disorder
    Russell C Dale
    Department of Child and Adolescent Psychiatry, PO Box 085, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
    Br J Psychiatry 187:314-9. 2005
    ..The proposed mediators are anti-basal ganglia antibodies (ABGA)...
  96. ncbi request reprint Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?
    Gavin Giovannoni
    Neurology 65:6-8. 2005
  97. ncbi request reprint Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report
    Hans P Hartung
    Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
    J Neurol 254:827-37. 2007
    ....
  98. ncbi request reprint Anti-neuronal antibodies and movement disorders
    Gavin Giovannoni
    J Neuroimmunol 163:5-7. 2005
  99. doi request reprint Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients
    Regina Lam
    Neuro Immunology Laboratory, University of British Columbia, Vancouver, Canada
    J Immunol Methods 336:113-8. 2008
    ..8-29.3%, and the intra-assay coefficient of variation was between 6.3-15.2%. The luciferase assay is reliable, appropriately sensitive and requires less time than the currently available NAb methods...
  100. ncbi request reprint Primary CNS mantle cell lymphoma associated with an isolated CSF monoclonal IgG band
    S Anand Trip
    Department of Clinical Neurology, Ipswich Hospital, Ipswich, UK
    Eur Neurol 49:187-8. 2003
  101. ncbi request reprint A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...